ALDX - Aldeyra Therapeutics, Inc.
NEXT EARNINGS:
Feb 27, 2026
(in 2 days)
EPS Est: $-0.14
|
Rev Est: $24.2M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$7.00
DETAILS
HIGH:
$7.00
LOW:
$7.00
MEDIAN:
$7.00
CONSENSUS:
$7.00
UPSIDE:
34.36%
Market Cap:
313.45M
Volume:
1,044,473
Avg Volume:
1,069,080
52 Week Range:
1.14-7.2
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.96
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
9
IPO Date:
2014-05-02
EPS (TTM):
-0.94
P/E Ratio:
-5.31
Revenue (TTM):
N/A
Total Assets:
104.61M
Total Debt:
15.30M
Cash & Equiv:
54.53M
Rev Growth (5Y):
N/A
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-62.7%
Debt/Equity:
0.22
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $-0.13 | $-0.17 | +23.5% | — | $24.2M | — |
| 2025-08-07 | $-0.16 | $-0.21 | +23.8% | — | — | — |
| 2025-05-14 | $-0.17 | $-0.25 | +32.0% | — | $-666670 | — |
| 2025-02-28 | $-0.27 | $-0.25 | -8.0% | $244526 | — | — |
| 2024-11-07 | $-0.25 | $-0.25 | 0.0% | — | $28.4M | — |
| 2024-08-01 | $-0.28 | $-0.14 | -100.0% | — | — | — |
| 2024-05-02 | $-0.14 | $-0.08 | -75.0% | — | $2.0M | — |
| 2024-03-07 | $-0.08 | $-0.21 | +61.9% | $392620 | $3.0M | -86.9% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (55.85M) | (37.54M) | (62.02M) | (57.78M) | (37.55M) | (60.83M) | (38.89M) | (22.34M) | (18.70M) | (12.09M) | (5.19M) | 13.06M |
| EPS | -0.94 | -0.64 | -1.06 | -1.07 | -1.11 | -2.24 | -1.79 | -1.40 | -1.65 | -1.40 | -1.36 | 39.90 |
| Total Assets | 104.61M | 148.33M | 181.29M | 233.14M | 83.35M | 75.52M | 95.09M | 44.17M | 25.19M | 28.20M | 8.79M | 3.74M |
| Total Debt | 15.30M | 15.66M | 16.08M | 15.86M | 15.33M | 14.75M | 0 | 1.34M | 1.32M | 1.29M | 1.25M | 1.27M |
| Cash & Equivalents | 54.53M | 142.82M | 144.42M | 229.79M | 77.86M | 44.43M | 47.36M | 20.02M | 12.02M | 14.65M | 8.53M | 3.26M |
| Operating Cash Flow | (43.21M) | (30.33M) | (56.64M) | (42.56M) | (37.49M) | (44.98M) | (29.86M) | (19.22M) | (15.15M) | (9.31M) | (4.78M) | (1.71M) |
| Free Cash Flow | (43.21M) | (30.33M) | (56.65M) | (42.56M) | (37.49M) | (44.99M) | (30.12M) | (19.25M) | (15.16M) | (9.40M) | (4.79M) | (1.71M) |
| FCF per Share | -0.73 | -0.51 | -0.97 | -0.79 | -1.10 | -1.66 | -1.39 | -1.21 | -1.34 | -1.09 | -1.25 | -0.42 |
| Book Value | 71.00M | 119.80M | 151.01M | 205.74M | 59.51M | 48.08M | 86.62M | 39.60M | 21.65M | 24.88M | 6.28M | (1.90M) |
| Cash & ST Investments | 101.15M | 142.82M | 174.30M | 229.79M | 77.86M | 73.36M | 93.60M | 42.95M | 24.91M | 27.59M | 8.53M | 3.26M |
| ROC Equity | -0.79 | -0.31 | -0.41 | -0.28 | -0.63 | -1.27 | -0.45 | -0.56 | -0.86 | -0.49 | -0.83 | N/A |